A new type of drug treatment for schizophrenia has successfully completed a phase 1 clinical trial.
Researchers in the Institute of Neuroscience have been collaborating with Autifony therapeutics Ltd to develop new treatments for serious conditions such as schizophrenia. A potential new drug treatment known as AUT00206 that has already shown to be effective in preclinical models of schizophrenia has now completed a phase 1 clinical trial. This means it has been given to healthy human volunteers to assess it's safety and pharmacokinetics, i.e. how long it takes to move through the body.
AUT00206 is a Kv3 modulator. This means it affects potassium channels in brain cells which in turn affects how these cells transmit messages to other cells. In particular it affects a type of brain cell called Parvalbumin interneurons, thought to be defective in schizophrenia.
In preclinical models AUT00206 proved effective on the wide range of symptoms associated with schizophrenia. It is hoped that this new class of drug will have an improved safety profile compared to current antipsychotic medications.
You can read the full press release on the Autifony website.